Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 9, 2004, Pages 3606-3609

  Falk, Rama ^a   Grunwald, Jacob ^b   Hoffman, Amnon ^b   Domb, Abraham J ^b   Polacheck, Itzhack ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B ARABINOGALACTAN CONJUGATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DERIVATIVE; AMPHOTERICIN B LIPID COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; KIDNEY; LIVER; LUNG; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; AREA UNDER CURVE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONY COUNT, MICROBIAL; GALACTANS; HALF-LIFE; KIDNEY; LIVER; LUNG; MALE; MICE; MICE, INBRED BALB C; TISSUE DISTRIBUTION;

EID: 4344606417     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.9.3606-3609.2004     Document Type: Article

References (15)

1. Adler-Moore, J., and R. T. Proffitt. 2002. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 49(Suppl. 1):21-30.
2. Adler-Moore, J. P., and R. T. Proffitt. 1993. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of AmB. J. Liposome Res. 3:429-450.
3. Butler, W. T. 1966. Pharmacology, toxicity, and therapeutic usefulness of amphotericin B. JAMA 195:371-375.
4. Denning, D. W., L. Hall, M. Jackson, and S. Hollis. 1995. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Antimicrob. Agents Chemother. 39:1809-1814.
5. Domb, A. J., G. Linden, I. Polacheck, and S. Benita. 1996. Nystatin-dextran conjugates: synthesis and characterization. J. Polym. Sci. Part A Polym. Chem. 34:1229-1236.
6. Duncan, R., S. Gac-Breton, R. Keane, R. Musila, Y. N. Sat, R. Satchi, and F, Searle. 2001. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release 74:135-146.
7. Dupont, B. 2002. Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother. 49(Suppl. 1):31-36.
8. Ehrenfreund-Kleinman, T., T. Azzam, R. Falk, I. Polacheck, J. Golenser, and A. J. Domb. 2002. Synthesis and characterization of novel water-soluble amphotericin B-arabinogalactan conjugates. Biomaterials 23:1327-1335.
9. Falk, R., A. J. Domb, and I. Polacheck. 1999. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate. Antimicrob. Agents Chemother. 43:1975-1981.
10. Golenser, J., S. Frankenburg, T. Ehrenfreund, and A. J. Domb. 1999. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives. Antimicrob. Agents Chemother. 43: 2209-2214.
11. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):133-144.
12. Maeda, M., C. Nishimura, D. Umeno, and M. Takagi. 1994. Psoralen-containing vinyl monomer for conjugation of double-helical DNA with vinyl polymers. Bioconjug. Chem. 5:527-531.
13. Meyer, R. D. 1992. Current role of therapy with amphotericin B. Clin. Infect. Dis. 14(Suppl. 1):154-160.
14. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A, 2nd ed., vol. 22. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Wingard, J. R., P. Kubilis, L. Lee, G. Yee, M. White, L. Walshe, R. Bowden, E. Anaissie, J. Hiemenz, and J. Lister. 1999. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29:1402-1407.